Concepedia

Sujatha Nallapareddy

SN

12

Publications

1.2K

Citations

12

H-Index

2005

Active since

Affiliations

University of Colorado Denver(Current)

University of Colorado Cancer Center

Roswell Park Comprehensive Cancer Center

The University of Texas MD Anderson Cancer Center

GlaxoSmithKline (United States)

Sujatha Nallapareddy is an author at University of Colorado Denver specializing in medicine, cancer research, and cancer therapeutics.

Top concepts

Publications per year

2005–2023

12

Publications

12

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

Jeffrey R. Infante, Leslie A. Fecher, Gerald S. Falchook et al. · The Lancet Oncology · 2012 · 554 citations

, , +7

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

John H. Strickler, Andrea Cercek, Salvatore Siena et al. · The Lancet Oncology · 2023 · 217 citations

, , +7

Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212.

J. R. Infante, Leslie A. Fecher, Sujatha Nallapareddy et al. · Journal of Clinical Oncology · 2010 · 121 citations

, , +21

Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K- <i>ras</i> –Mutated Colorectal Cancer

John J. Tentler, Sujatha Nallapareddy, Aik Choon Tan et al. · Molecular Cancer Therapeutics · 2010 · 74 citations · Full text

INTERLEUKIN-6 POLYMORPHISM IS ASSOCIATED WITH MORE AGGRESSIVE PROSTATE CANCER

Dongfeng Tan, Xiuxian Wu, Min Hou et al. · The Journal of Urology · 2005 · 68 citations

Rows per page

1–5 of 12